Program areas at Global HIV Vaccine Enterprise
Meetings/program - a) strategic convening/timely topics in Hiv vaccines series: the search for a safe and effective Hiv Vaccine has progressed further and faster in the last few years than at any time since the epidemic began. This progress poses new questions, new opportunities and new challenges as to what and how the Hiv Vaccine research endeavor should move forward. To help identify and respond to unresolved and emerging priority issues and move Hiv Vaccine r&d forward, the Enterprise produces its timely topics in Hiv vaccines series. Through an open call for proposals, the Enterprise identifies the most strategic needs of the field and sponsors think tanks, meetings, forums and other events in addition to developing useful tools to tackle these issues. Issues addressed to date include vaccine-induced sero-positivity/ sero-reactivity, a mucosal guide, and antibody durability, among others. B) to strengthen recognition of the Enterprise mission, programs, stakeholder goals and achievements, as well as keep current on the state of Hiv Vaccine research, the Enterprise secretariat participated in various scientific and advisory meetings and discussions with partners and stakeholders. Through these interactions, the Enterprise helped to connect partners, coordinate efforts, share information, and support stakeholders in coordinated Vaccine research and development efforts.
Conference - Hiv research for prevention (r4p) conference: the Global Hiv Vaccine Enterprise (Enterprise) began preparations for the hivr4p conference to be held from october 21st to 25th, 2018 in madrid, spain. This biennial conference is the leading Global forum for scientific exchange on Hiv Vaccine research and helps to increase coordination in our collective effort to develop an Hiv Vaccine. The conference will be attended by more than 1400 researchers, funders, advocates, and policymakers, feature daily plenary presentations by leading researchers and clinicians along with symposia and oral abstract and poster sessions addressing every aspect of Vaccine development and testing. Hivr4p 2018 will host many opportunities for young and early career investigators to share ideas and approaches and network with peers and senior researchers.
Who funds Global HIV Vaccine Enterprise
Federal funding details
Federal agency | CFDA code | Program name | Amount |
---|
Department of Health and Human Services | 93.855 | ALLERGY IMMUNOLOGY AND TRANSPLANTATION RESEARCH | $1,237,249 |
National Science Foundation | 47.079 | OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING | $711,338 |
Financials for Global HIV Vaccine Enterprise
Revenues | FYE 12/2017 | FYE 12/2016 | % Change |
---|
Total grants, contributions, etc. | $1,160,530 | $4,269,284 | -72.8% |
Program services | $0 | $617,585 | -100% |
Investment income and dividends | $0 | $61 | -100% |
Tax-exempt bond proceeds | $0 | $0 | - |
Royalty revenue | $0 | $0 | - |
Net rental income | $0 | $0 | - |
Net gain from sale of non-inventory assets | $0 | $0 | - |
Net income from fundraising events | $0 | $0 | - |
Net income from gaming activities | $0 | $0 | - |
Net income from sales of inventory | $0 | $0 | - |
Miscellaneous revenues | $0 | $39,938 | -100% |
Total revenues | $1,160,530 | $4,926,868 | -76.4% |
Organizations like Global HIV Vaccine Enterprise
Organization | Type | Location | Revenue |
---|
International Psoriasis Council | 501(c)(3) | St Charles, MO | $1,444,073 |
Center for European Policy Analysis (CEPA) | 501(c)(3) | Washington, DC | $4,926,107 |
Owl Research Institute | 501(c)(3) | Charlo, MT | $331,772 |
Armenian Assembly of America | 501(c)(3) | Washington, DC | $5,328,433 |
Arava Institute for Environmental Studies | 501(c)(3) | Newton Center, MA | $2,209,397 |
Creative Commons Corporation | 501(c)(3) | Mountain View, CA | $3,267,812 |
International Conservation Caucus Foundation (ICCF) | 501(c)(3) | Washington, DC | $3,000,029 |
The Ursa Institute | 501(c)(3) | San Francisco, CA | $765,454 |
George C Marshall Institute | 501(c)(3) | Arlington, VA | $319,092 |
Institute for Energy Research (IER) | 501(c)(3) | Washington, DC | $1,225,208 |
Data update history
October 28, 2020
Updated personnel
Identified 1 new personnel
March 5, 2020
Used new vendors
Identified 1 new vendor, including
July 24, 2019
Updated personnel
Identified 10 new personnel
December 30, 2018
Used new vendors
Identified 2 new vendors, including , and
November 26, 2018
Posted financials
Added Form 990 for fiscal year 2017
Nonprofit Types
Social advocacy organizationsResearch centers
Issues
Social sciencesDiseases and disorders
Characteristics
Conducts researchOperates internationallyNational levelReceives government fundingTerminated
General information
- Address
- 64 Beaver St Suite 352
- New York, NY 10004
- Metro area
- New York-Newark-Jersey City, NY-NJ-PA
- County
- New York County, NY
- Website URL
- iasociety.org/ias-programme/global-hiv-vaccine-enterpriseÂ
- Phone
- (212) 461-3692
- Facebook page
- hiventerpriseÂ
IRS details
- EIN
- 20-3347314
- Fiscal year end
- December
- Taxreturn type
- Form 990
- Year formed
- 2005
- Eligible to receive tax-deductible contributions (Pub 78)
- No
Categorization
- NTEE code, primary
- V00: Social Science Research: General
- NAICS code, primary
- 813319: Social Advocacy Organizations
- Parent/child status
- Independent
Free account sign-up
Want updates when Global HIV Vaccine Enterprise has new information, or want to find more organizations like Global HIV Vaccine Enterprise?
Create free Cause IQ account